EWTX
Edgewise Therapeutics Inc.
Company Overview
| Mkt Cap | $1.82B | Price | $22.67 |
| Volume | 1.28M | Change | +1.89% |
| P/E Ratio | -13.6 | Open | $22.20 |
| Revenue | -- | Prev Close | $22.25 |
| Net Income | $-133.8M | 52W Range | $10.60 - $35.50 |
| Div Yield | N/A | Target | $37.77 |
| Overall | 63 | Value | 60 |
| Quality | -- | Technical | 66 |
No chart data available
About Edgewise Therapeutics Inc.
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. The company was incorporated in 2017 and is headquartered in Boulder, Colorado.
Latest News
Edgewise Therapeutics (EWTX) Gets a Buy from Evercore ISI
Piper Sandler Sticks to Its Buy Rating for Edgewise Therapeutics (EWTX)
Edgewise Therapeutics Appoints New Chief Financial Officer
H.C. Wainwright Sticks to Their Buy Rating for Edgewise Therapeutics (EWTX)
Edgewise Therapeutics’ EDG-7500 Study: A Potential Game Changer for Renal Impairment Treatment?
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | EWTX | $22.67 | +1.9% | 1.28M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Edgewise Therapeutics Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW